rs200092211
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_000726.5(CACNB4):c.5C>T(p.Ser2Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000877 in 1,533,242 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000726.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000907 AC: 138AN: 152112Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00145 AC: 195AN: 134704Hom.: 0 AF XY: 0.00121 AC XY: 88AN XY: 72796
GnomAD4 exome AF: 0.000873 AC: 1206AN: 1381012Hom.: 1 Cov.: 31 AF XY: 0.000889 AC XY: 606AN XY: 681524
GnomAD4 genome AF: 0.000907 AC: 138AN: 152230Hom.: 0 Cov.: 32 AF XY: 0.000954 AC XY: 71AN XY: 74426
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:3
The S2F variant of unknown significance has not been published as a pathogenic variant, nor has it been reported as a benign polymorphism to our knowledge. The 1000 Genomes Project reports S2F was observed in 1/214 alleles (0.5%) from individuals of Italian background (McVean et al., 2012). The S2F variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution alters a highly conserved position in the N-terminal region of the CACNB4 protein, and in silico analysis predicts this variant is probably damaging to the protein structure/function. However, to date only a small number of substitutions in CACNB4 have been published in association with epilepsy, and no pathogenic variants have been reported in the N-terminal region of the protein (Escayg et al., 2000; Ohmori et al., 2008). Therefore, based on the currently available information, it is unclear whether S2F is a pathogenic or a rare benign variant. -
- -
- -
- -
CACNB4: BS1, BS2 -
not specified Uncertain:1Benign:1
- -
- -
Epilepsy, idiopathic generalized, susceptibility to, 9 Uncertain:1
- -
Episodic ataxia type 5;C2750887:Epilepsy, idiopathic generalized, susceptibility to, 9 Uncertain:1
- -
Juvenile myoclonic epilepsy Benign:1
- -
CACNB4-related disorder Benign:1
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Episodic ataxia type 5 Benign:1
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
Idiopathic generalized epilepsy Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at